KaloBios Pharmaceuticals Inc (KBIO.OQ)

KBIO.OQ on NASDAQ Stock Exchange Global Market

2.04USD
11 Jul 2014
Price Change (% chg)

$0.04 (+2.00%)
Prev Close
$2.00
Open
$2.01
Day's High
$2.07
Day's Low
$2.00
Volume
2,174
Avg. Vol
63,981
52-wk High
$6.53
52-wk Low
$1.68

KBIO.OQ

Chart for KBIO.OQ

About

KaloBios Pharmaceuticals, Inc., is a United States-based company, which develops protein therapeutics. The Company develops and engineers antibodies and protein therapeutics. Its monoclonal antibodies (mAbs) technology that is being used for reengineering antibodies with products being developed in the areas of infectious... (more)

Overall

Beta: --
Market Cap (Mil.): $65.96
Shares Outstanding (Mil.): 32.98
Dividend: --
Yield (%): --

Financials

  KBIO.OQ Industry Sector
P/E (TTM): -- 99.11 35.83
EPS (TTM): -1.44 -- --
ROI: -69.34 -0.58 18.29
ROE: -78.88 -1.43 19.18
Search Stocks

DIARY-U.S. MEETINGS/WEEK AHEAD

THOMSON REUTERS, June 18,2014 - Corporate Meetings for US companies for Week ahead. S&P 500 Earnings - Weekly S&P 500 Earnings - Day Ahead Non S&P 500 - Weekly Non S&P 500 - Day Ahead ConferenceCall/Webcast - Weekly ConferenceCall/Webcast - Day S&P 500 Earnings - Monthly Meetings - Day Ahead Economic Indicators Dividends Daily earnings hits & misses Federal Res

18 Jun 2014

KaloBios Pharma pulls plug on asthma drug, shares plunge

- Shares of KaloBios Pharmaceuticals Inc fell nearly 50 percent in extended trade after the company said it would stop developing an asthma drug that failed in a mid-stage study.

29 Jan 2014

KaloBios Pharma pulls plug on asthma drug, shares plunge

Jan 29 - Shares of KaloBios Pharmaceuticals Inc fell nearly 50 percent in extended trade after the company said it would stop developing an asthma drug that failed in a mid-stage study.

29 Jan 2014

Competitors

  Price Change
Takeda Pharmaceutical Co Ltd (4502.T) ¥4,663 +8.00
Pfizer Inc. (PFE.N) $29.84 -0.16
Novartis AG (NOVN.VX) CHF79.55 -0.10
Roche Holding Ltd. (ROG.VX) CHF262.50 +0.30
Amgen, Inc. (AMGN.OQ) $119.94 +0.99

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks